

COVID-19 and Monkeypox Situational Report in the ASEAN+3 Region

— ASEAN BioDiaspora Virtual Center (ABVC)



Table of Contents

COVID-19	1
Highlights and Situation Overview	1
Global Update	1
Regional Update	1
Vaccine Update	2
Research Update	2
Cases and Deaths Table	4
Epi curve Among ASEAN Countries	5
Weekly COVID-19 New Cases and New Deaths	6
Vaccination Status in ASEAN	7
Outlook Assessment	8
Monkeypox	9
Monkeypox Cases Globally Map	9
Highlights and Situation Overview	10
Monkeypox Cases in ASEAN+3 Region Table	10
Top 5 Countries with Most Cases Globally	10
Monkeypox per Region Other than ASEAN+3	10
Research Update	11
Vaccine Update	11
References	12



COVID-19: Highlights and Situation Overview

Global Update

- **Worldwide**, there have been over 627 million cases and over 6 million deaths attributed to COVID-19.
- **UK:** (06 October 2022) According to official statistics, over a million persons in the UK stated they had long COVID symptoms for at least a year, and over half a million indicated they had symptoms for at least two years. In comparison to the last survey up to July 31, 1.1 million people with self-reported protracted COVID—up from 892,000—said they had been suffering symptoms for at least a year since acquiring COVID-19. And 514,000 people—up from 429,000 in July—said the symptoms had lasted for two years or longer. 1.6 million persons had their daily activities negatively impacted by long-term COVID symptoms, with 342,000 reporting that their capacity to do so had been "restricted a lot." According to official statistics, over a million persons in the UK stated they had long COVID symptoms for at least a year, and over half a million indicated they had symptoms for at least two years. In comparison to the last survey up to July 31, 1.1 million people with self-reported protracted COVID—up from 892,000—said they had been suffering symptoms for at least a year since acquiring COVID-19. And 514,000 people—up from 429,000 in July—said the symptoms had lasted for two years or longer. 1.6 million persons had their daily activities negatively impacted by long-term COVID symptoms, with 342,000 reporting that their capacity to do so had been "restricted a lot."
- **EU:** The pooled rate in Europe for all age groups has been rising for the past 3 weeks, and the effect on seniors is leading to rising hospital indicators. The European Centre for Disease Prevention and Control (ECDC) said the rise in cases is likely due to changes in population mixing following the summer break, with no indication that the rise is linked to changes in circulating SAR-CoV-2 variants. However, deaths continue to fall noting that deaths declined 10% last week compared to the week before. The agency said forecasts predict that deaths will start showing an increasing trend in the middle of October. Similarly, the United Kingdom's Health Security Agency (HSA) said that most COVID indicators rose last week, with hospital admissions still highest in people ages 85 and older. Meanwhile, Denmark's cases rose last week in all five of its regions where hospitalizations rose in people ages 70 to 89, making up the largest proportion of new COVID admissions. However, officials added that intensive care unit (ICU) admissions remain very low.
- **USA:** The US Centers for Disease Control and Prevention (CDC) in its latest variant proportion updates said that the percentage of BA.5 continues to decline slowly. The BA.5 proportion dropped from 81.5% to 79.2% of sequenced samples. Meanwhile, the BF.7 subvariant rose from 3.3% to 4.6%, BA.2.72 rose from 1.5% to a share of 1.8%, and BA.4.6 rose slightly from 12.7% to 13.6%.

Regional Update

- **Philippines:** If public health precautions are not followed, COVID-19 infections might reach 4,000 to over 8,000 by the end of October, the Department of Health said on October 10.⁸ Data as of mid-September showed that cases were expected to "follow a continuous slow downward trend," according to DOH Epidemiology Bureau Director Alethea De Guzman in a briefing.⁸ FASSSTER, a web application for developing disease models for diseases and for visualizing syndromic surveillance, projected 1,204 cases per day by the end of the month under this scenario.⁸ By the end of October, illnesses might vary from 4,055 to 8,670, depending on how well minimal public health guidelines are followed.⁸ [[Full Article](#)]



- **Singapore's** Ministry of Health announced that all vaccination-differentiated safe management measures (VDS) will be fully lifted starting October 10 (Monday). With the lifting, VDS will not be required for events with more than 500 participants at any time, nightlife establishments, and dining in at food/beverage establishments (including hawker centers). However, even as VDS is lifted, non-fully vaccinated persons continue to face a higher risk of severe disease. MOH also clarified that should the situation worsen, MOH may need to put in place necessary measures at short notice to protect the public.

Vaccine Update

- **Singapore's** Ministry of Health has recommended Moderna's bivalent COVID vaccine for 18 and above. According to the Expert Committee on COVID-19 Vaccination, this updated vaccine is preferred over the original COVID-19 vaccines, and as such the primary vaccination series for those yet to be vaccinated should also be switched to the new bivalent vaccine where possible. The committee said that individuals who have received their second booster should be offered a booster dose of the bivalent vaccine around five months after their last booster dose when it is available. Hence, persons aged 50 and above can receive up to five vaccine shots including the bivalent vaccine. Starting October 17, persons aged 50 and above and those who are yet to achieve minimum protection will be able to receive the bivalent vaccine. The rest of the population will be offered the vaccine as more doses arrive. The committee also recommends the use of the bivalent vaccine for the primary vaccination series for those aged 18 years and above but Pfizer-BioNTech and Novavax/Nuvaxovid vaccines will still be available for the time being for those who prefer it. However, the bivalent vaccine is not available for persons under 18 years as it has not undergone trials in this age group. Furthermore, children aged six months to four years can receive their primary vaccination with the Moderna Spikevax vaccine and those aged five to 11 years can receive a booster dose with Pfizer- BioNTech/Comirnaty vaccine starting October 25.
- **Indonesia:** The population still requires the third or booster dosage of the COVID-19 vaccine, according to Prof. Tjandra Yoga Aditama, a health specialist, even if the number of cases has decreased and the pandemic's conclusion is in sight.⁷ According to data from the World Health Organization (WHO), COVID-19 incidence in Southeast Asia has decreased by 17% as of October 5, 2022.⁷ In a statement released on October 9, the professor stated that in line with the Director General of the WHO, Tedros Adhanom Ghebreyesus, individuals must exert their greatest efforts in the last stages of the epidemic to put an end to it.⁷ Aditama, a professor at the Faculty of Medicine of the University of Indonesia and a former director of infectious diseases at WHO South-East Asia, stated that Indonesia's vaccination coverage still needs to be increased because, as of now, only about 62% of the population has received all recommended vaccinations.⁷ [\[Full Article\]](#)

Research Update

- In the ***Association Between Vaccination Status and Mortality Among Intubated Patients with COVID-19-Related Acute Respiratory Distress Syndrome*** study, among 265 patients who required invasive mechanical ventilation due to COVID-19-related acute respiratory distress syndrome, complete vaccination status was linked to a decreased death rate compared to controls after controlling for covariates.⁴ [\[Full Text\]](#)
- In the ***Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and inhospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study*** showed that early use of the innovative oral antivirals molnupiravir and nirmatrelvir with ritonavir during Hong Kong's wave of SARS-CoV-2



omicron subvariant BA.2.2 was linked to lower risks of mortality and in-hospital illness progression in patients with COVID-19.⁵ [\[Full Text\]](#)

- In the ***Association of the COVID-19 Pandemic with Prehospital Characteristics and Outcomes of Pediatric Patients With Out-of-Hospital Cardiac Arrest in Japan, 2005-2020***, one of the main causes of mortality and a significant public health issue is sudden cardiac arrest.⁶ There is a correlation between the COVID-19 pandemic and poorer adult out-of-hospital cardiac arrest (OHCA) outcomes in several pre- and post-COVID-19 comparisons.⁶ In contrast, this study found that pediatric OHCA patients' survival rates were stable during the COVID-19 pandemic, indicating that the virus was not significantly linked to these outcomes.⁶ [\[Full Text\]](#)



Cases and Deaths as of 10 October 2022

- As of 10 October 2022 (2PM, GMT+8), worldwide, there were **627,169,211** confirmed cases, including **6,570,750** deaths. Globally, Case Fatality Rate (CFR) was **1.1**.
- 89,648,003 confirmed cases** of COVID-19 have been reported in the **ASEAN +3** countries including **34,588,525 cases** in the ASEAN region and **55,059,478 cases** in the PLUS THREE countries.
- The Case Fatality Rate in the **ASEAN +3** region is range between **0.1 to 3.1**
- There have been no tests reported in the last 14 days in the **ASEAN** Region.

REGION	COUNTRY	FIRST CONFIRMED CASE(S)	LATEST REPORT ON CONFIRMED CASE(S)	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED	FULLY VACCINATED/ 100
ASEAN REGION	Brunei	10 Mar 20	09-Oct-22	227,756	-	225	-	52,565	449,769	444,757	335,738	99.9
	Cambodia	27 Jan 20	09-Oct-22	137,927	6	3,056	-	837	15,191,537	14,543,659	10,164,757	87.7
	Indonesia	02 Mar 20	09-Oct-22	6,444,948	999	158,205	7	2,382	204,187,550	170,774,653	63,398,160	62.4
	Lao PDR	24 Mar 20	09-Oct-22	215,995	2	758	-	3,013	5,888,649	5,222,417		70.3
	Malaysia	25 Jan 20	09-Oct-22	4,854,976	1,453	36,400	2	15,196	28,104,321	27,512,529	16,750,909	82.0
	Myanmar	23 Mar 20	09-Oct-22	625,497	-	19,464	-	1,157	34,777,314	27,545,329	2,227,351	51.2
	Philippines	30 Jan 20	09-Oct-22	3,967,861	1,996	63,264	34	3,670	77,569,580	72,976,259	19,110,988	64.1
	Singapore	23 Jan 20	09-Oct-22	1,945,019	6,198	1,629	1	34,102	5,161,644	5,121,063	4,418,394	93.9
	Thailand	13 Jan 20	09-Oct-22	4,682,132	-	32,771	-	6,725	57,005,497	53,486,086	32,143,431	74.7
	Vietnam	23 Jan 20	09-Oct-22	11,486,414	371	43,153	-	11,908	89,975,153	84,234,230	69,805,302	86.4
ASEAN COUNTRIES				34,588,525	11,025	358,925	44	131,553	518,311,014	461,860,982	218,355,030	
ASEAN PLUS THREE	South Korea	20-Jan-20	09-Oct-22	24,970,789	17,654	28,675	29	48,291	45,115,032	44,681,456	41,079,395	86.2
	Japan	16-Jan-20	09-Oct-22	21,161,401	-	44,576	-	16,760	104,228,721	102,866,426	118,068,839	82.6
	China	31-Dec-19	09-Oct-22	8,927,288	49,942	26,977	65	53,443	1,332,009,024	1,299,094,080	833,295,358	87.8
	PLUS THREE COUNTRIES				55,059,478	67,596	100,228	94	118,494	1,481,352,777	1,446,641,962	992,443,592
ASEAN +3				89,648,003	78,621	459,153	138	250,046	1,999,663,791	1,908,502,944	1,210,798,622	


- 537,521,208 confirmed cases** of COVID-19 have been reported in **5 continents** (other than ASEAN +3 countries):

CONTINENT	TOTAL CONFIRMED CASES	NEW CASES	TOTAL DEATHS	NEW DEATHS	CUMULATIVE CASES/ 100,000	CUMULATIVE VACCINATED	CUMULATIVE FULLY VACCINATED	CUMULATIVE BOOSTERED
AFRICA	12,911,568	45	258,638	-	241,508	408,574,355	324,848,740	52,191,169
AMERICAS	181,911,583	13,863	2,879,254	98	1,184,742	824,974,016	723,242,256	477,490,191
ASIA PACIFIC	85,463,837	3,026	750,649	24	474,346	1,445,268,330	1,337,189,624	392,005,290
EUROPE	234,774,464	148,711	1,984,942	246	2,007,770	566,164,986	537,412,601	357,554,749
MIDDLE EAST	22,459,756	1,397	238,114	8	211,689	144,036,793	129,388,263	59,383,677
TOTAL	537,521,208	167,042	6,111,597	376	4,120,054	3,389,018,480	3,052,081,484	1,338,625,076



COVID-19 Epi curve among ASEAN Countries:

From January 1, 2021 to October 9, 2022




Cumulative cases of COVID-19 in the ASEAN Region as of October 9, 2022 (Report generated by ASEAN Biodiaspora Virtual Center)

*Data from Bluedot Insights, cases may differ from how data is reported in countries and other authorities. Data may be subject to retrospective correction by national authorities.



Weekly COVID-19 New Cases and New Deaths


From January 1, 2021 to October 9, 2022





COVID-19 Vaccination Status


as of 09 October 2022





COVID-19 Outlook Assessment

as of 07 October 2022

 ASEAN MEMBER STATE	At least 65% of the total population has a level of immunity to COVID-19; either recovered from COVID-19 or have been vaccinated with at least one dose of a COVID-19 vaccine.		Case levels are generally low (a 7-day rolling average number of daily new cases that is <10 cases per 100,000, with each day's past-14-day test positivity is consistently <5%).		Government Policy on containment and health (strictness and comprehensiveness in COVID-19 related government policies)
	% of Total population fully vaccinated / boosted	Population vaccinated/ day (7-day average)	Daily cases/ 100,000	Test positivity last 14 days	Containment and health index score -Oxford COVID-19 Government Response Tracker (OxCGRT)
Brunei	≥90.0/75.4	Unknown	0.00	Unknown	31.0/100
Cambodia	≥90.0/61.3	Unknown	0.04	Unknown	31.5/100
Indonesia	65.4/23.0	Unknown	0.56	Unknown	54.2/100
Lao PDR	77.3/ND	Unknown	0.27	Unknown	61.6/100
Malaysia	84.4/49.9	0.01%/day	4.12	Unknown	51.8/100
Myanmar	52.1/4.1	Unknown	0.71	Unknown	69.1/100
Philippines	70.6/16.8	Unknown	1.86	Unknown	55.4/100
Singapore	≥90.0/81.0	0%/day	85.90	Unknown	58.9/100
Thailand	77.7/44.9	0%/day	0.00	Unknown	31.5/100
Vietnam	≥90.0/71.6	Unknown	0.89	Unknown	43.5/100
Japan	81.3/≥94.1	0%/day	0.00	Unknown	42.9/100
South Korea	86.5/79.3	0%/day	43.41	Unknown	38.1/100
China	≥90.0/56.5	Unknown	0.021	Unknown	84.5/100

All of the countries have achieved the estimated high-risk population fully vaccinated of ≥90.0% except China with 35.3%.

All of the countries have achieved the Population vaccinated/ day (7-day average) except Vietnam.



Monkeypox: Highlights and Situation Overview

- As of 10 October 2022 (2PM, GMT+8), worldwide, there were **74,059** confirmed cases, including **174** deaths. Globally, Case Fatality Rate (CFR) was **0.23%**.
- **54 confirmed cases** of Monkeypox have been reported in the **ASEAN+3** region composed of **35 cases** in the ASEAN region and **19 cases** in the PLUS THREE countries, with CFR of **0%**.
- **74,005 confirmed cases** of Monkeypox have been reported in other **5 regions** (other than ASEAN +3 countries):

Monkeypox cases in ASEAN+3 region

Region	Country	Total Cases	New Cases	Deaths	Case Fatality Rate
ASEAN	Singapore	19	-	-	0.00%
ASEAN	Thailand	10	-	-	0.00%
Plus Three	Japan	6	-	-	0.00%
Plus Three	China	5	-	-	0.00%
ASEAN	Philippines	4	-	-	0.00%
Plus Three	Taiwan	4	-	-	0.00%
Plus Three	South Korea	3	-	-	0.00%
ASEAN	Indonesia	1	-	-	0.00%
ASEAN	Vietnam	1	-	-	0.00%
Plus Three	Hong Kong (SAR)	1	-	-	0.00%
ASEAN+3 Total		54	-	-	0.00%

Top 5 countries with most monkeypox cases globally

Region	Country	Total Cases	New Cases	Deaths	Case Fatality Rate
Americas	USA	26,311	0	2	0.01%
Americas	Brazil	7,869	0	2	0.03%
Europe	Spain	7,209	0	3	0.04%
Europe	France	3,999	0	-	0.00%
Europe	United Kingdom	3,654	0	-	0.00%

Monkeypox cases per region other than ASEAN+3

REGION	TOTAL CONFIRMED CASES SINCE JANUARY 1, 2022	NEW CASES SINCE THE PREVIOUS REPORT	TOTAL DEATHS	CASE FATALITY RATE
AFRICA	4,781	1	160	3.35%
AMERICAS	44,187	6	8	0.02%
ASIA PACIFIC	166	2	1	0.61%
EUROPE	24,573	0	5	0.02%
MIDDLE EAST	298	0	-	0.00%
TOTAL	74,005	9	174	0.23%



Research Update

- There are no treatments specifically for monkeypox virus infections.³ However, monkeypox and smallpox viruses are genetically similar, and therapeutics developed to combat smallpox may be used to treat monkeypox.³ The antiviral agents tecovirimat and brincidofovir have activity against monkeypox virus.³ Data from randomized clinical trials are urgently needed to address the expanding monkeypox outbreak.³ [\[Full Text\]](#)

Vaccine Update

- **New Zealand:** Monkeypox is now being spread among the community in Aotearoa, but a vaccination to protect those who are most vulnerable won't be accessible until at least December. Officials revealed the first two MPX community transmission incidences on October 6.¹ Nine reported cases were previously thought to be imported.¹ To ensure a steady supply of the smallpox vaccination Jynneos, Pharmac is collaborating with Te Whatu Ora (Health New Zealand).¹ However, a Te Whatu Ora spokeswoman claimed that due to Jynneos' limited worldwide availability and strong demand, dosages were expected to be available for New Zealand "from December".¹ The completion of the contract between Pharmac and the supplier was a condition of this deadline.¹ [\[Full Article\]](#)
- **Brazil:** The first supply of monkeypox vaccinations arrived in Brazil (October 4, 2022).² The Ministry of Health will employ the batch of 9,800 dosages of Jyneos/MVA-BN in research projects.² The study intends to track data on the disease vaccine's safety, immunogenicity, and effectiveness. World Health Organization recommendation (WHO).² The investigations will be supported by the WHO and sponsored by Fiocruz (Fundação Oswaldo Cruz) and the Ministry of Health.² The Pan American Health Organization, researchers, and subject-matter specialists have all been consulted by the Brazilian authorities over the study.² The target group consists of those who have been exposed to the virus, i.e., those who have had repeated contact with an infected person, as well as those who have not yet been exposed but are on pre-exposure prophylaxis (PrEP) or receiving antiretroviral treatment for HIV.² The priority group for immunization does not include medical professionals.² The Ministry of Health claims that because this organization collects and treats patients with individualized protective equipment, epidemiological statistics from Brazil and throughout the globe do not indicate a higher exposure to the disease (PPE).² A specialist may be chosen to get the vaccination in the event of extended unprotected contact with a confirmed case.² [\[Full Article\]](#)



References

1. Martin H. Monkeypox vaccine not expected in NZ until December as community spread confirmed. Stuff. <https://www.stuff.co.nz/national/health/300707315/monkeypox-vaccine-not-expected-in-nz-until-december-as-community-spread-confirmed>. Published 2022. Accessed October 10, 2022.
2. Hargraves A. The first batch of new smallpox vaccines will be used in research. brytfmonline. <https://www.brytfmonline.com/the-first-batch-of-new-smallpox-vaccines-will-be-used-in-research/>. Published 2022. Accessed October 10, 2022.
3. McCarthy M. Therapeutic strategies to address monkeypox. *Expert Rev Anti Infect Ther*. 2022;20(10):1249-1252. doi:10.1080/14787210.2022.2113058
4. Grapsa E, Adamos G, Andrianopoulos I et al. Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19–Related Acute Respiratory Distress Syndrome. *JAMA Netw Open*. 2022;5(10):e2235219. doi:10.1001/jamanetworkopen.2022.35219
5. Grapsa E, Adamos G, Andrianopoulos I et al. Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19–Related Acute Respiratory Distress Syndrome. *JAMA Netw Open*. 2022;5(10):e2235219. doi:10.1001/jamanetworkopen.2022.35219
6. Zha L, Hosomi S, Kiyohara K, Sobue T, Kitamura T. Association of the COVID-19 Pandemic With Prehospital Characteristics and Outcomes of Pediatric Patients With Out-of-Hospital Cardiac Arrest in Japan, 2005-2020. *JAMA Netw Open*. 2022;5(10):e2235401. doi:10.1001/jamanetworkopen.2022.35401
7. Bhwana P. Booster Dose Still Needed Despite Decline in COVID-19 Cases, Says Health Expert. Tempo. <https://en.tempo.co/read/1643447/booster-dose-still-needed-despite-decline-in-covid-19-cases-says-health-expert>. Published 2022. Accessed October 10, 2022.
8. Cabico G. 4,000 daily COVID-19 cases seen by end-October if decreased compliance continues. Philstar. <https://www.philstar.com/headlines/2022/10/10/2215655/4000-daily-covid-19-cases-seen-end-october-if-decreased-compliance-continues>. Published 2022. Accessed October 10, 2022.



Report generated by
ASEAN Biodiaspora Virtual Center (ABVC)
 in collaboration with **Bluedot Inc.**
 Email: support@biodiaspora.org
 Facebook: <https://facebook.com/ASEANBiodiaspora>



In partnership with
Canada